EUVIMEDObjevte EUVIMED
Crossref

Utility of Fluorescence In Situ Hybridization as a Fetal Surgery Eligibility Criterion for Isolated Congenital Anomalies When Non‐Invasive Screening Is Performed

Ethan Lorence iD, Katelyn Seither iD, Hua He, Kara B Markham iD, Beatrix Wong

Prenatal Diagnosis · 2026

DOI: 10.1002/pd.70068 ↗

At a glance

Journal article in Prenatal Diagnosis, 2026. Written by Ethan Lorence and 4 co-authors. Institution: Department of Pediatrics, Division of Human Genetics of the College of Medicine at the University of Cincinnati, Cincinnati, Ohio, USA. Major MEDLINE topics: In Situ Hybridization, Fluorescence, Congenital Abnormalities, Noninvasive Prenatal Testing. 15 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

Current inclusion criteria for fetal surgery at most centers include the absence of multiple major anomalies and a normal chromosome analysis or fluorescence in situ hybridization (FISH) for aneuploidy. We evaluated the concordance of FISH with non‐invasive screening methodologies to determine if invasive genetic testing provides additional information on fetal surgery candidacy.

Methods

A retrospective chart review was performed on 963 pregnancies evaluated for fetal surgery at the Cincinnati Children's Hospital Fetal Care Center between July 1, 2018 and July 31, 2023 for genetic testing results, fetal imaging, and surgical candidacy.

Results

FISH was concordant with screening results in 100% of pregnancies whose imaging and cell‐free fetal DNA screening suggested a fetus at low risk for trisomy 21, trisomy 18, trisomy 13, and sex chromosome aneuploidies. Pregnancies with multiple congenital anomalies were significantly more likely to have abnormal genetic testing compared to pregnancies with isolated anomalies (52% vs. 17%, P = 0.0009).

Conclusions

In this study cohort, FISH did not provide additional information for the risk‐benefit analysis of fetal surgery and introduced additional risk to the pregnancy due to the need for invasive fetal DNA collection.

Subjects

MeSH terms (MEDLINE)

In Situ Hybridization, FluorescenceCongenital AbnormalitiesNoninvasive Prenatal TestingHumansFemalePregnancyRetrospective StudiesAdultGenetic TestingPrenatal Diagnosis

Authors and institutions

  • Department of Pediatrics, Division of Human Genetics of the College of Medicine at the University of Cincinnati, Cincinnati, Ohio, USA.
  • Department of Human Genetics at the Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Precision Medicine Institute at TriHealth, Cincinnati, Ohio, USA.
  • Cincinnati Children's Fetal Care Center, Cincinnati, Ohio, USA.
  • Cincinnati Children's Hospital Medical Center, Division of Neonatology and Pulmonary Biology, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

ORCID profiles: Ethan Lorence, Katelyn Seither, Kara B Markham

Cite

APA

Lorence, E., Seither, K., He, H., Markham, K. B., & Wong, B. (2026). Utility of Fluorescence In Situ Hybridization as a Fetal Surgery Eligibility Criterion for Isolated Congenital Anomalies When Non‐Invasive Screening Is Performed. Prenatal Diagnosis. https://doi.org/10.1002/pd.70068

Vancouver

Lorence E, Seither K, He H, Markham KB, Wong B. Utility of Fluorescence In Situ Hybridization as a Fetal Surgery Eligibility Criterion for Isolated Congenital Anomalies When Non‐Invasive Screening Is Performed. Prenatal Diagnosis. 2026. doi:10.1002/pd.70068

BibTeX
@article{Lorence2026,
  author = {Lorence, Ethan and Seither, Katelyn and He, Hua and Markham, Kara B and Wong, Beatrix},
  title = {Utility of Fluorescence In Situ Hybridization as a Fetal Surgery Eligibility Criterion for Isolated Congenital Anomalies When Non‐Invasive Screening Is Performed},
  journal = {Prenatal Diagnosis},
  year = {2026},
  doi = {10.1002/pd.70068}
}
Start for free →